Flotation

SI-Bone burrows into public markets with $108m IPO
The Novo-backed surgical implant provider floated at the top of its range and increased the number of shares in the offering.
Equillium enters public markets
Existing investor Biocon bought more shares in a $65.4m offering that involved the immuno-inflammatory disorder drug developer floating at the bottom of its range.
Allogene closes IPO at nearly $373m
The underwriters took up the option to buy another 2.7 million shares after the Pfizer and Gilead-backed oncology therapy developer's shares leapt substantially post-IPO.
Anaplan raises $264m in IPO
Anaplan has raised close to $264m in its flotation on the New York Stock Exchange that provided exits for Salesforce and Workday.
Allogene rallies to $324m IPO
The Pfizer and Gilead-backed immuno-oncology therapy developer, which had raised $300m in an April series A round, floated at the top of its range.
Guardant Health gets to public markets with $238m
The SoftBank-backed precision oncology test developer floated above its range and saw its share price rise 69% on the first day of trading.
CooTek cooks up US flotation
The SIG China-backed mobile app developer raised $52.2m despite floating at the bottom of the IPO's range.
Liulishuo passes IPO exam
Liulishuo has listed on the New York Stock Exchange following a $71.9m initial public offering that provided an exit to publishing house Hearst.

Other News

Gritstone rocks $100m IPO
The Eli Lilly-backed immuno-oncology product developer floated at the top of its range, with Bluebird Bio investing $10m.
Sutro seals $86m IPO
Immunotherapy developer Sutro Biopharma has floated on the Nasdaq Global Market, providing exits for Merck & Co, Celgene, Amgen and Eli Lilly.
Funding Circle rings up $576m IPO
The lending platform's existing shareholders, which include Rocket Internet, sold $184m in shares as part of the offering.
SurveyMonkey adds surplus to close IPO at $207m
The underwriters for the initial public offering have bought another $27m in shares in the Alphabet and Salesforce-backed online survey platform developer.
Viomi connects to Nasdaq in flotation
The home IoT platform floated at the foot of its range to raise almost $103m, while Xiaomi will retain a 16.4% stake in the company.
Entasis enters public markets with $75m
The Astra Zeneca antibiotic development spin off has floated in an initial public offering in which Novo bought more than $16m in shares.

Editor's Picks

Allogene rallies to $324m IPO
The Pfizer and Gilead-backed immuno-oncology therapy developer, which had raised $300m in an April series A round, floated at the top of its range.
Guardant Health gets to public markets with $238m
The SoftBank-backed precision oncology test developer floated above its range and saw its share price rise 69% on the first day of trading.
SurveyMonkey surges to $180m IPO
The online survey platform, which counted Alphabet and Salesforce as investors, floated above its range while increasing the number of shares in the IPO.
Nio parks in public markets with $1bn
The Tencent,Baidu, Lenovo and JD.com-backed electric carmaker floated near the foot of its range at a reported $6.4bn valuation.
test reg

Login

Not yet subscribed?

See your subscription offers here